CY1124643T1 - Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης - Google Patents

Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης

Info

Publication number
CY1124643T1
CY1124643T1 CY20211100780T CY211100780T CY1124643T1 CY 1124643 T1 CY1124643 T1 CY 1124643T1 CY 20211100780 T CY20211100780 T CY 20211100780T CY 211100780 T CY211100780 T CY 211100780T CY 1124643 T1 CY1124643 T1 CY 1124643T1
Authority
CY
Cyprus
Prior art keywords
group
atom
acceptable salt
pharmaceutically acceptable
hydrogen atom
Prior art date
Application number
CY20211100780T
Other languages
English (en)
Inventor
Keiji Tamura
Takeru Yamakawa
Satoshi ISSHIKI
Yoshinari Wakiyama
Shohei Ouchi
Takashi MATSUHIRA
Natsuki Ishida
Yuji Tabata
Original Assignee
Meiji Seika Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co., Ltd. filed Critical Meiji Seika Pharma Co., Ltd.
Publication of CY1124643T1 publication Critical patent/CY1124643T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ένωση που αντιπροσωπεύεται από το γενικό τύπο (1) πιο κάτω ή φαρμακολογικά αποδεκτό άλας αυτής: [Στον τύπο (1), τα R1 και R2 μπορεί να είναι τα ίδια ή διαφορετικά και το καθένα αντιπροσωπεύει άτομο υδρογόνου, άτομο αλογόνου, υδροξυλομάδα, ομάδα καρβοξυ, ομάδα κυανό, μια προαιρετικά υποκατεστημένη C1-6αλκυλομάδα κ.α.· το R3 αντιπροσωπεύει ένα άτομο υδρογόνου· το R4 αντιπροσωπεύει μια προαιρετικά υποκατεστημένη 4-10μελή μονοκυκλική ετεροκυκλική ομάδα που περιέχει 1 έως 4 ετεροάτομα επιλεγμένα από άτομο οξυγόνου, άτομο αζώτου και άτομο θείου· το Χ αντιπροσωπεύει μια ομάδα που αντιπροσωπεύεται από τον ακόλουθο τύπο: -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, ή -CH2-O-CH2-, και το Ζ αντιπροσωπεύει ένα άτομο υδρογόνου ή μια υδροξυλομάδα.]
CY20211100780T 2016-12-26 2021-09-01 Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης CY1124643T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016251577 2016-12-26
JP2017089251 2017-04-28
PCT/JP2017/046610 WO2018124060A1 (ja) 2016-12-26 2017-12-26 新規化合物及びその薬理的に許容される塩

Publications (1)

Publication Number Publication Date
CY1124643T1 true CY1124643T1 (el) 2022-11-25

Family

ID=62709343

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100780T CY1124643T1 (el) 2016-12-26 2021-09-01 Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης

Country Status (22)

Country Link
US (1) US10669283B2 (el)
EP (1) EP3560925B1 (el)
JP (1) JP6815417B2 (el)
KR (1) KR102414365B1 (el)
CN (1) CN110114358B (el)
AU (1) AU2017385199B2 (el)
BR (1) BR112019010571A2 (el)
CA (1) CA3048170A1 (el)
CY (1) CY1124643T1 (el)
DK (1) DK3560925T3 (el)
ES (1) ES2875548T3 (el)
HU (1) HUE055468T2 (el)
IL (1) IL267594B (el)
MX (1) MX2019007684A (el)
PH (1) PH12019501391A1 (el)
PL (1) PL3560925T3 (el)
PT (1) PT3560925T (el)
RU (1) RU2767878C2 (el)
TW (1) TWI752141B (el)
UA (1) UA124353C2 (el)
WO (1) WO2018124060A1 (el)
ZA (1) ZA201904241B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
JP6815566B2 (ja) * 2018-06-27 2021-01-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
JP2022533007A (ja) 2019-04-30 2022-07-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド
CN111057075B (zh) * 2019-12-24 2021-04-27 武汉九州钰民医药科技有限公司 Ret抑制剂及其制备方法
US20240309010A1 (en) 2021-06-30 2024-09-19 Meiji Seika Pharma Co., Ltd. Method for producing benzoxazole derivative having bicyclic piperazine ring or salt thereof, and method for producing material thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166827A (ja) 1985-01-17 1986-07-28 Toray Ind Inc 変性エポキシ系微粒子
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
KR101129933B1 (ko) * 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
CN101160307A (zh) * 2005-02-17 2008-04-09 Amr科技公司 用于治疗cinv和ibs-d的苯并噁唑甲酰胺
KR101417159B1 (ko) * 2006-08-07 2014-07-16 알바니 몰레큘라 리써치, 인크. 5ｈｔ3 조절제로서의 2-아미노벤족사졸 카르복스아미드
JP5563466B2 (ja) * 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
ES2714705T3 (es) * 2013-07-10 2019-05-29 Meiji Seika Pharma Co Ltd Inhibidor de PDE4 novedoso

Also Published As

Publication number Publication date
ZA201904241B (en) 2020-12-23
CN110114358A (zh) 2019-08-09
HUE055468T2 (hu) 2021-11-29
NZ754689A (en) 2024-04-26
TWI752141B (zh) 2022-01-11
EP3560925A1 (en) 2019-10-30
AU2017385199A1 (en) 2019-07-04
UA124353C2 (uk) 2021-09-01
BR112019010571A2 (pt) 2019-09-17
EP3560925A4 (en) 2020-06-10
CN110114358B (zh) 2021-12-03
PT3560925T (pt) 2021-07-28
EP3560925B1 (en) 2021-06-02
AU2017385199B2 (en) 2021-09-09
US20190322686A1 (en) 2019-10-24
RU2019122999A3 (el) 2021-03-31
US10669283B2 (en) 2020-06-02
MX2019007684A (es) 2019-09-09
TW201835080A (zh) 2018-10-01
RU2767878C2 (ru) 2022-03-22
WO2018124060A1 (ja) 2018-07-05
KR20190097235A (ko) 2019-08-20
JP6815417B2 (ja) 2021-01-20
IL267594B (en) 2022-04-01
PH12019501391A1 (en) 2020-02-10
ES2875548T3 (es) 2021-11-10
RU2019122999A (ru) 2021-01-26
JPWO2018124060A1 (ja) 2019-10-31
KR102414365B1 (ko) 2022-07-01
CA3048170A1 (en) 2018-07-05
PL3560925T3 (pl) 2021-12-20
DK3560925T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
CY1122614T1 (el) 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1121867T1 (el) Αναστολεις jak2 και alk2 και μεθοδοι για τη χρηση τους
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
MX2017005769A (es) Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre.
MX2017000305A (es) Derivados heterociclicos activos con sustituyentes que contienen azufre como plaguicidas.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
EA201690127A1 (ru) Состав на основе ингибиторов syk
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
MY182124A (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
MY165215A (en) Pyridone derivatives
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
MX2016012448A (es) Derivados heterociclicos que contienen sustituyentes de tipo azufre activos como plaguicidas.
MX2017013678A (es) Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof